PreOmics and Biognosys win US patent challenge against Seer patent
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
PreOmics GmbH and Biognosys AG Prevail in U.S. Patent Challenge
March 31, 2026 1:07 PM EDTUS PTAB Revokes Sole Independent and Other Central Claims of U.S. Patent 11,435,360
SCHLIEREN, Switzerland & MUNICH--(BUSINESS WIRE)-- PreOmics GmbH and Biognosys AG today announced a favorable outcome in an inter partes review (IPR) proceeding IPR202401473 before the U.S. Patent Trial and Appeal Board (PTAB). The PTAB has revoked the central claims of U.S. Patent No. 11,435,360, which is owned by The Brigham and Womens Hospital, and exclusively licensed to Seer, Inc.
The USPTO struck... More
